Influenza picking up in U.S., predominantly A(H3N2)

Influenza picking up in U.S., predominantly A(H3N2)

(HealthDay)—Influenza activity was low during October 2017 but started increasing in November, with influenza A, predominantly A(H3N2), most commonly identified, according to research published in the Dec. 8 issue of the U.S. Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report.

Vivien G. Dugan, Ph.D., from the CDC in Atlanta, and colleagues summarized U.S. during Oct.1 to Nov. 25, 2017.

The researchers note that influenza activity was low during October 2017 in the United States, but since the start of November, activity has been increasing. The most commonly identified viruses have been influenza A viruses, with influenza A(H3N2) predominating. Several indicators of influenza activity were reported to be higher than normally seen at this time of year. Most influenza viruses characterized during this period were genetically or antigenically similar to the Northern Hemisphere cell-grown vaccine reference viruses for 2017 to 2018. Currently circulating viruses seem not to have undergone significant antigenic drift; circulating A(H3N2) viruses are antigenically less similar to egg-grown A(H3N2) viruses used for most U.S. influenza vaccine production. Hospitalizations and deaths were more common and was lower in recent past seasons in which A(H3N2) viruses predominated; it is unclear which influenza viruses will predominate in the 2017 to 2018 season.

"Vaccination should continue to be offered as long as are circulating and unexpired vaccine is available," the authors write.

One author disclosed holding two patents relating to influenza vaccines.

More information: Abstract/Full Text

Copyright © 2017 HealthDay. All rights reserved.

Citation: Influenza picking up in U.S., predominantly A(H3N2) (2017, December 8) retrieved 28 March 2024 from https://medicalxpress.com/news/2017-12-influenza-predominantly-ah3n2.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

H3N2 mutation in last year's flu vaccine responsible for lowered efficacy

1 shares

Feedback to editors